Microba Life Sciences (ASX: MAP) is an Australian-listed company in the Healthcare sector with a market capitalisation of $19.5M and the 1289th-largest security on the ASX by market capitalisation. The MAP share price is $0.038, down 5.00% today and down 54.76% over the past 12 months. Shares have traded between $0.037 and $0.105 over the past 52 weeks. In its most recent reported period (ending 31 Dec 2025), Microba Life Sciences reported revenue of $7.3M and a net loss of $10.6M.
About Microba Life Sciences Limited
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
